Key result
The paper provides standardized methodological protocols for evaluating blood coagulation in mice, including tail bleeding time, prothrombin time, and activated partial thromboplastin time.
Why the study?
Genetically modified mouse technologies provide new models for investigating blood coagulation regulation, but many genomic variants affecting hemostasis remain unknown.
Standardizes murine coagulation assays for reproducible preclinical data; leaves open translation to human cardiovascular practice.
The mammalian blood coagulation system was designed to restrict blood loss due to injury as well as keep the blood fluid within the blood vessels of the organism. Blood coagulation activity in inbred mouse strains varies widely among strains, suggesting that many genomic variants affect hemostasis. Some of these molecules have been discovered and characterized; however, many are still unknown. Genetically modified mouse technologies are providing a plethora of new mouse models for investigating the regulation of blood coagulation. Here we provide a protocol for the tail bleeding time as a primary assessment of in vivo blood coagulation, as well as in vitro methods such as the prothrombin time, activated partial thromboplastin time, and thrombin generation assay. We also provide protocols for the assessment of the activities of specific known factors involved in blood coagulation.
No takes yet. Share an insight, caveat, or question.
Brake et al. (2019) studied Blood coagulation and hemostasis (preclinical models). Coagulation assessment protocols was evaluated. The paper provides standardized methodological protocols for evaluating blood coagulation in mice, including tail bleeding time, prothrombin time, and activated partial thromboplastin time.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: